Page Banner
Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Renal

Renal

The highest standards in renal diagnostics

Partnering with BioPharma Diagnostics gives you access to over 150 years of advanced medical knowledge. Our renal diagnostics are backed by a multidisciplinary approach and an award-winning team of Mayo Clinic nephrology experts, pathologists, and laboratory scientists who work at the intersection of research and patient care. We believe laboratory medicine offers more than a test result — it is about collaboration to advance kidney disease research and develop new, innovative therapies that have the potential to improve patient outcomes.

Mayo Clinic Laboratories is at the forefront of renal testing innovation, offering a suite of novel artificial intelligence algorithms that optimize operational workflows and accuracy of kidney stone analysis.  

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Full suite of renal testing Full suite of renal testing
Full suite of RENAL testing

Our renal diagnostics are backed by a multidisciplinary approach and an award-winning team of Mayo Clinic nephrology experts, pathologists, and laboratory scientists who work at the intersection of research and patient care.

Glomerular disease Glomerular disease
Glomerular disease 

Glomerular diseases include several conditions that can damage the kidneys’ filtering units, the glomeruli, resulting in protein and red blood cells leaking into the urine. We offer testing for glomerulonephritis, membranous nephropathy, and more.

Kidney function Kidney function
Kidney function

We offer a menu of kidney function tests, including both serum and urine evaluations, to analyze kidney health. Using both common and esoteric assays, a team of Mayo Clinic nephrology physicians and laboratory scientists built our data-driven testing, which uses innovative laboratory technology to monitor all stages of kidney disease.

Renal genetics Renal genetics
Renal genetics

A team of Mayo Clinic nephrology and geneticist experts developed our renal testing program, which is among the most comprehensive diagnostic testing available. Our evaluations use next-generation sequencing to evaluate clinically relevant genes across multiple disease states.

Renal pathology Renal pathology
Renal pathology

Mayo Clinic Laboratories integrates with the anatomic pathology laboratories in the Department of Laboratory Medicine and Pathology at Mayo Clinic. The fusion of our multispecialty pathology team with our comprehensive approach provides an ideal environment to diagnose renal pathology while keeping care local.

Urinary stone services Urinary stone services
Urinary stone services 

To optimize patient care, our kidney stone services help identify metabolic and physical compositions. Our comprehensive approach and concise report support your practice with accurate interpretation to guide clinical decisions.

Comprehensive disease testing

A collaboration with BioPharma Diagnostics includes access to the renal testing capabilities of Mayo Clinic Laboratories, including:

  • Glomerular disease
  • Kidney function
  • Renal genetics
  • Renal pathology
  • Urinary stone services
News and updates

The latest

A blue gloved hand examining kidney stones.
Accurate Kidney Stone Analysis

This microlearning will familiarize users on MCL's AI-augmented kidney stone test along with the proper procedures for collecting and processing kidney stones to provide accurate, cost-effective, and timely analysis of the stones.

Learn more
It Remains Unknown: Link between Gadolinium Exposure via MRI Exams and Health Effects in Patients with Normal Renal Function

There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul Jannetto, Ph.D., DABCC, FAACC, and Joshua Bornhorst, Ph.D., DABCC, FAACC, Co-Directors of the Mayo Clinic Metals Laboratory and leading experts in this field, have compiled the following list of the most up-to-date information.

New Biomarker Greatly Improves Diagnostic Sensitivity for Rare Kidney Disease, Fibrillary Glomerulonephritis

A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.